Table 1

Baseline Characteristics

BMMC (n = 30)G-CSF (n = 30)BMMC + G-CSF (n = 29)Control Subjects (n = 31)p Value
Age, yrs54 ± 1157 ± 956 ± 857 ± 110.591
Male29 (97)25 (83)25 (86)28 (90)0.375
Hypertension8 (27)12 (40)9 (31)14 (45)0.426
Diabetes mellitus5 (17)3 (10)7 (24)3 (10)0.356
Hyperlipidemia17 (57)15 (50)11 (38)11 (35)0.299
Smoking history25 (83)26 (87)21 (72)24 (77)0.529
Family history of coronary disease5 (17)6 (20)7 (24)10 (32)0.508
Previous history of coronary disease2 (7)3 (10)1 (3)1 (3)0.644
Coronary artery disease0.693
 1-vessel disease23 (77)22 (73)22 (76)22 (71)
 2-vessel disease6 (20)8 (27)7 (24)7 (23)
 3-vessel disease1 (3)0 (0)0 (0)2 (6)
Infarct-related artery0.077
 Left anterior descending coronary artery20 (67)20 (67)24 (83)21 (68)
 Left circumflex artery0 (0)4 (13)0 (0)1 (3)
 Right coronary artery10 (33)6 (20)5 (17)9 (29)
PCI in noninfarct-related arteries18 (60)14 (47)15 (52)20 (65)0.497
Time from symptom onset to primary PCI, h4 (3–6)3 (2–5)4 (1–6)3 (3–7)0.818
Time from symptom onset to post-fibrinolysis PCI, h14 (8–23)18 (8–30)16 (7–23)17 (9–23)0.779
Maximal creatine kinase, x ULN3,641 ± 3,0752,880 ± 1,4943,838 ± 1,9302,980 ± 2,1790.247
Maximal creatine kinase MB, x ULN337 ± 262321 ± 198350 ± 223328 ± 2090.972
Maximal troponin T, x ULN11 ± 813 ± 3022 ± 4519 ± 370.514
NT-proBNP at randomization, x ULN1,213 ± 1,4441,178 ± 1,1651,400 ± 6981,836 ± 1,6570.361
Time from reperfusion to G-CSF administration, h39 (27–44)44 (30–48)0.251
Time from reperfusion to intracoronary infusion of cells, h190 (164–216)190 (178–212)0.358
Bone marrow aspiration volume, ml60 (31–65)55 (20–70)0.319
Number of injected cells, x 10683 (60–117)560 (351–915)<0.001
 Viability, %89 ± 991 ± 60.321
 CD34+, %1.03 (0.41–1.08)0.31 (0.19–1.14)<0.001
 CD34+, absolute number x 1060.83 (0.33–2.07)2.93 (0.69–22.6)<0.001
 CD133+, %0.55 (0.24–0.85)0.23 (0.08–0.41)<0.001
 CD133+, absolute number x 1060.38 (0.15–1.1)2.4 (0.4–14.3)<0.001
 CD117+, %1.27 (0.67–2.04)0.4 (0.19–1.6)<0.001
 CD117+, absolute number x 1061.14 (0.37–2.78)3.23 (0.81–32.7)<0.001
Medication at discharge
 Aspirin27 (90)29 (100)25 (93)30 (97)0.314
 Clopidogrel30 (100)29 (100)27 (100)30 (97)0.424
 Beta-blocker28 (93)24 (83)24 (89)29 (94)0.481
 ACE inhibitor or AT II blocker26 (87)24 (83)23 (85)23 (74)0.588
 Diuretics2 (7)3 (11)4 (15)2 (7)0.670
 Statins28 (93)28 (97)27 (100)30 (97)0.590
Medication at 12 months follow-up
 Aspirin27 (90)27 (93)26 (96)26 (87)0.603
 Clopidogrel29 (97)28 (97)27 (100)30 (100)0.579
 Beta-blocker26 (87)26 (89)25 (93)27 (90)0.909
 ACE inhibitor or AT II blocker29 (97)26 (90)27 (100)29 (97)0.271
 Diuretics0 (0)4 (14)8 (30)6 (20)0.017
 Statins30 (100)29 (100)26 (96)29 (97)0.548

Values are mean ± SD, n (%), or median (range with the minimal and maximal observations).

ACE = angiotensin-converting enzyme; AT = angiotensin; BMMC = bone marrow mononuclear cell(s); CD = cluster of differentiation; G-CSF = granulocyte colony-stimulating factor; NT-proBNP = N-terminal pro–B-type natriuretic peptide; PCI = percutaneous coronary intervention; ULN = upper limit of normal.